Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics

February 14, 2023

New York, NY, and Tel Aviv, ISRAEL, Feb. 14, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical, Ltd. (OTCQB:TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has initiated a validation plan for PCR-based Avian Influenza A (H5N1, bird flu) human testing. Under the plan, the Company will validate commercial and internally developed H5N1 PCR reagents and launch the most sensitive test. The H5N1 PCR test is being developed as a Laboratory Developed Test (LDT).

Read more at globenewswire.com

Related news for (TOMDF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.